Contact | 
Print version | 
PDF version | 
Send article | 
RSS feed
Symphogen A/S and Biovitrum AB enter into agreement for anti-Rhesus D antibodies
03 Feb 2006 -
Symphogen A/S and Biovitrum AB have entered into a co-development and commercialization agreement for Sym001, Symphogen's lead product. Sym001 is a combination of 25 different recombinant anti-Rhesus D antibodies for the treatment of both Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of the Newborn (HND).
Under the terms of the new collaboration agreement, Symphogen receives an initial technology access fee from Biovitrum and will receive milestone payments based on the progress of the program. Symphogen will be responsible for marketing in North America, Central America and South America, and Biovitrum for Europe, Russia and the Middle East. The companies will seek partners for remaining rest of world markets. The companies will equally share the costs for developing anti-RhD and will divide future commercial profits evenly. Additional financial terms will not be disclosed.
Manufacture of Sym 001 has been successfully scaled up under good manufacturing practice (GMP) conditions at Biovitrum that, prior to this agreement, has been contract manufacturing the product for initial clinical trials. Clinical trials will commence in 2006.
The total global market for the ITP indication is estimated to be worth about USD 500 million annually and for the HDN indication about USD 200 million per year.
Top
